https://www.selleckchem.com/pr....oducts/lurbinectedin
Unlike well-established diseases that base clinical care on randomized trials, past experiences, and training, prognosis in COVID19 relies on a weaker foundation. Knowledge from other respiratory failure diseases may inform clinical decisions in this novel disease. The objective was to predict 48-hour invasive mechanical ventilation (IMV) within 48h in patients hospitalized with COVID-19 using COVID-like diseases (CLD). This retrospective multicenter study trained machine learning (ML) models on patients hospitalized with CLD to p
إعجاب
علق
شارك
